search
Back to results

Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. (PROMILD)

Primary Purpose

ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Patients will receive MV in PP
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ARDS focused on measuring ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit, ICU, Prone position

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of 18 years or more admitted to ICU.
  • ARDS patients meeting the Berlin criteria under invasive mechanical ventilation within the first 24h.
  • Mechanically ventilated patients with standard settings: PEEP of 5 cmH2O or more and VT 6 ml/kg PBW and Pplat equal to or below 28-30 cmH2O after intubation.
  • PaO2/FIO2 between 150 and 300 mmHg under previous settings within 12 hours after mechanical ventilation standardization.
  • Written informed consent obtained from the patient, next of kin/proxy or emergency consent. The patient will be asked to give his consent for the continuation of the trial when his condition will allow.

Exclusion Criteria:

  • Contra-indication to PP: spine instability; intracranial pressure greater than 20 mmHg; severe facial trauma; hemodynamic instability
  • Non-inclusion criteria related to medical condition: Lung transplant; Burns over more than 20% of body surface; Chronic respiratory failure requiring home oxygen supplementation and/or non-invasive ventilation; Underlying disease with death expectancy within one year;
  • Other non-inclusion criteria: Therapeutic limitation; inclusion into another interventional study in intubated and ventilated patients with mortality as primary end-point in the last 30 days; previously included in the same study; prone positioning before inclusion.
  • Individuals referred to in Articles L. 1121-5 à L. 1121-7 (pregnant women, persons deprived of freedom, minors), adult individuals under protection of law (L. 1121-8 and L. 1122-1-2) (emergency situations) of public health regulation in France
  • Patients not affiliated to social security insurance regimen

Sites / Locations

  • Grenoble University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Patients will receive MV in PP

Patients will receive MV in SP

Arm Description

Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met

Outcomes

Primary Outcome Measures

All-cause mortality
All-cause mortality 28 days after inclusion

Secondary Outcome Measures

Full Information

First Posted
September 14, 2021
Last Updated
November 2, 2022
Sponsor
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT05056090
Brief Title
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
Acronym
PROMILD
Official Title
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
September 28, 2023 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute respiratory distress syndrome (ARDS) accounts for almost 10% of intensive care units (ICU) admissions. Three ARDS stages have been defined, based on the PaO2/FIO2 ratio measured with positive end-expiratory pressure (PEEP) ≥5 cmH2O: mild (201-300 mmHg), moderate (200-101 mmHg), and severe (≤100mmHg). They represent 30.0%, 46.6%, and 23.4% of ARDS, respectively. Mechanical invasive ventilation (MV), the cornerstone of ARDS patient care, has a primary goal to protect the lung from ventilator-induced lung injury (VILI). Delivering MV in a prone position (PP) has been shown to improve oxygenation, protect the lung through a better homogenization of lung stress/strain, and stabilize hemodynamics. A meta-analysis of four randomized controlled trials showed beneficial effect of PP vs. supine position (SP) in the most hypoxemic patients. A fifth randomized controlled trial further showed a significant reduction in mortality with PP in ARDS patients with PaO2/FIO2 <150 mmHg, when neuromuscular blockade and long prone positioning sessions were used. Therefore, PP has since been strongly recommended for ARDS patients with PaO2/FIO2 <150 mmHg. Yet, there is limited evidence in patients with mild to moderate ARDS. There are, however, strong arguments supporting the need for a new trial in ARDS patients with PaO2/FIO2 in the range 150-300 mmHg: There is no trial that has specifically tested PP in this ARDS subset; PP is safe and has become a standard of care in ICU; Should VILI prevention be a mechanism through which PP improves survival, this should be involved in all ARDS patients; The mortality at hospital discharge in this subset of ARDS remains significant, amounting to 34.9% (95% confidence intervals 31.4-38.5%) in mild and 40.3% (37.4-43.3) in moderate stages; Among 580 patients with mild ARDS at admission to the ICU, in-hospital mortality was 10%, 30%, and 37% for those who improved, persisted, and worsened ARDS, respectively. Finally, PP has been shown to be cost-effective under commonly accepted thresholds. The hypothesis is that in patients within the 150-300mmHg PaO2/FIO2 range at the time of ARDS diagnosis, PP can reduce mortality as compared to a similar group left in the SP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit, Mechanical Ventilation
Keywords
ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit, ICU, Prone position

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
prospective, randomized, multicenter, open label trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
656 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients will receive MV in PP
Arm Type
Experimental
Arm Description
Patients assigned to the intervention group will be turned in PP within the two hours after randomization for at least 16 consecutive hours. Then, patients will be turned in SP. Then, PP sessions are repeated as long as stopping criteria for PP are not met
Arm Title
Patients will receive MV in SP
Arm Type
No Intervention
Intervention Type
Procedure
Intervention Name(s)
Patients will receive MV in PP
Intervention Description
Putting the patient in a prone position
Primary Outcome Measure Information:
Title
All-cause mortality
Description
All-cause mortality 28 days after inclusion
Time Frame
28 days after inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 18 years or more admitted to ICU. ARDS patients meeting the Berlin criteria under invasive mechanical ventilation within the first 24h. Mechanically ventilated patients with standard settings: PEEP of 5 cmH2O or more and VT 6 ml/kg PBW and Pplat equal to or below 28-30 cmH2O after intubation. PaO2/FIO2 between 150 and 300 mmHg under previous settings within 12 hours after mechanical ventilation standardization. Written informed consent obtained from the patient, next of kin/proxy or emergency consent. The patient will be asked to give his consent for the continuation of the trial when his condition will allow. Exclusion Criteria: Contra-indication to PP: spine instability; intracranial pressure greater than 20 mmHg; severe facial trauma; hemodynamic instability Non-inclusion criteria related to medical condition: Lung transplant; Burns over more than 20% of body surface; Chronic respiratory failure requiring home oxygen supplementation and/or non-invasive ventilation; Underlying disease with death expectancy within one year; Other non-inclusion criteria: Therapeutic limitation; inclusion into another interventional study in intubated and ventilated patients with mortality as primary end-point in the last 30 days; previously included in the same study; prone positioning before inclusion. Individuals referred to in Articles L. 1121-5 à L. 1121-7 (pregnant women, persons deprived of freedom, minors), adult individuals under protection of law (L. 1121-8 and L. 1122-1-2) (emergency situations) of public health regulation in France Patients not affiliated to social security insurance regimen
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laura CHAMBON
Phone
+33476768955
Email
lchambon@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
CRA Sponsor
Phone
+33476766862
Email
Arcmoniteur@chu-grenoble.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolas TERZI
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grenoble University Hospital
City
Grenoble
ZIP/Postal Code
38000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roselyne COLLOMB-MURET
Phone
+33476767109
Email
rcollombmuret@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Pierre NICOLAS
Phone
+33476767109
Email
pnicolas@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Nicolas TERZI

12. IPD Sharing Statement

Learn more about this trial

Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.

We'll reach out to this number within 24 hrs